Suetsugu Takayuki, Tsuruzono Kentaro, Hatanaka Masashi, Yamaguchi Akihiro, Yonezawa Hajime, Umehara Tadashi, Mizuno Keiko, Tanaka Kentaro, Seki Naohiko, Inoue Hiromasa
Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan.
Department of Neurosurgery, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan.
Respirol Case Rep. 2025 May 6;13(5):e70206. doi: 10.1002/rcr2.70206. eCollection 2025 May.
A 60-year-old man diagnosed with lung adenocarcinoma underwent standard left lower lobectomy. However, he developed brain metastasis 10 months later, and the metastatic lesion was resected surgically. At that time, the KRAS G12C mutation was detected in the metastatic tissue by the Oncomine Dx Target Test. After 16 months, liver metastases appeared, and treatment with sotorasib was initiated. Unexpectedly, however, Sotorasib was ineffective, and the disease progressed. Cancer Genome Profiling (CGP) Test revealed that mutations of and were already present in the patient's primary tumour, resulting in the initial resistance to standard targeted therapy.
一名60岁被诊断为肺腺癌的男性接受了标准的左下肺叶切除术。然而，10个月后他发生了脑转移，转移灶被手术切除。当时，通过Oncomine Dx Target Test在转移组织中检测到KRAS G12C突变。16个月后，出现了肝转移，开始使用索托拉西布进行治疗。然而，出乎意料的是，索托拉西布无效，疾病进展。癌症基因组分析（CGP）测试显示，患者的原发性肿瘤中已经存在 和 的突变，导致对标准靶向治疗产生初始耐药性。
